8-6-13 4:05 PM EDT | Email Article

Company Reports Earnings per Diluted Share of $0.51, Exceeds Company Guidance

Company Plans to Pursue Strategic Sale of Existing Corporate Medifast Weight Control Centers

OWINGS MILLS, Md., Aug. 6, 2013 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, today reported financial results for the second quarter ended June 30, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20120613/NE24271LOGO-b )

"We are pleased with our ability to increase earnings ahead of our expectations for the second quarter," commented Michael C. MacDonald, Medifast's Chairman and Chief Executive Officer. "We improved our overall operational performance in the quarter and remain focused on planning our investments and initiatives to maximize profitability long-term. To this point, today we announced plans to pursue the strategic sale of our existing corporate Medifast Weight Control Centers and transition them to the franchise model over the next 12 to 18 months.  We continue to be optimistic about our overall future growth prospects across Take Shape for Life, Medifast Direct, Medifast Weight Control Centers, and Wholesale Physicians."

Second Quarter 2013 Results 

For the second quarter ended June 30, 2013, Medifast net revenue increased 4% to $97.1 million from net revenue of $93.6 million in the second quarter of 2012.  

Revenue in the direct sales channel, Take Shape for Life, increased 10% to $61.4 million in the second quarter of 2013 compared to $55.7 million in the same period last year. Growth in revenue for Take Shape for Life was driven by increased customer product sales and improvements in the Company's pricing and discounting structure. The Company ended the second quarter with approximately 11,800 active health coaches, an increase of 17% as compared to the same period last year. The average revenue per health coach per month for the quarter increased to $1,690 compared to $1,683 in the second of 2012. The Company recently hosted a successful Take Shape for Life Annual Convention with over 3,000 attendees, a 27% increase versus the prior year. At the Convention, new products and new health coach tools were launched to increase a coaches' ability to attract new clients, retain existing clients, and help them further grow their businesses.

The Company's Medifast Direct channel revenue decreased 4% to $21.5 million, compared to $22.5 million in the second quarter of 2012.  In evaluating a more challenging consumer discretionary spending environment, the Company closely managed advertising and marketing investments.   Also, as disclosed in the first quarter of 2013, in addition to the continued focus on direct response and call to action marketing, the Company allocated a portion of second quarter spending to brand building and awareness creation messaging.  This has resulted in a significant improvement in brand awareness from 25% to 40% in the last 18 months, from 32% to 40% in the last 6 months alone, and is expected to contribute to long-term overall revenue growth for the Company.  Consolidated Company advertising spending in the second quarter of 2013 decreased 11% to $8.0 million compared to $9.0 million in the second quarter of 2012.  In the second quarter of 2013, the Company's overall revenue to spend ratio of 12.1-to-1 versus 10.3-to-1 in the second quarter of 2012 highlights the focus on spending efficiency.  For the remainder of 2013, the Company plans to spend conservatively and will continue to monitor all elements of its advertising mix to improve near term demand generation for the Medifast Direct sales division while continuing to build brand awareness long term.     

In the second quarter, the Medifast Weight Control Centers and Wholesale Physicians channel revenue decreased 8% to $14.2 million. In the second quarter of 2013, while same store sales for corporate centers opened greater than one year decreased 20%, the Company realized a $0.3 million profit improvement as compared to the second quarter of 2012. The increase was the result of savings from the staffing re-alignment completed in the first quarter of 2012, continued efforts to optimize staffing levels following the restructuring, and reduced advertising spending.  The Company ended the second quarter with a total of 86 corporate locations, of which 85 were in the comparable store base as of June 30, 2013, and 36 franchise locations. Today, the Company also announced plans to sell the existing corporate centers and transition them to the franchise model over the next 12 to 18 months.  This will allow the Company to optimize franchise performance, heighten focus on franchise location expansion with both existing and new franchise partners, and provide a strong foundation for future growth and profitability. 

Gross profit for the second quarter of 2013 increased 4% to $72.9 million, compared to $70.1 million in the second quarter of the prior year. The Company's gross profit margin increased 10 basis points to 75.1% in the second quarter versus 75.0% in the second quarter of 2012. Gross margin improvement during the quarter was the result of offering fewer customer discounts, partially offset by increased commodity and shipping costs. 

Selling, general and administrative expenses (SG&A) were $62.3 million compared to $65.5 million in the second quarter of 2012, a decrease of $3.2 million.  As a percentage of revenue, SG&A decreased 580 basis points to 64.2% versus 70.0%. Excluding the previously disclosed FTC charge of $3.7 million in the second quarter of 2012, SG&A in 2012 would have been $61.8 million or 66.1% of net revenue.

Operating income was $10.6 million, or 11.0% of net revenue, compared to $4.6 million, or 4.9% of net revenue in the second quarter of 2012. Excluding the previously disclosed FTC charge in the second quarter of 2012, operating income increased $2.3 million or 210 basis points. Operating income for the second quarter of 2012 would have been $8.3 million or 8.9% of net revenue excluding the one-time expense.

The Company had an effective tax rate of 35.0% compared to 48.9% in the second quarter of 2012. The decrease in the effective tax rate was primarily the result of the absence of non-deductible cost associated with the FTC settlement in 2012.

Net income was $7.1 million, or $0.51 per diluted share, based on approximately 14.0 million shares outstanding compared to net income last year of $2.8 million, or $0.20 per diluted share.  Excluding the FTC charge, net income in the second quarter of 2012 would have been $6.5 million, or $0.47 per diluted share.

Balance Sheet 

The Company's balance sheet remains strong with stockholders' equity of $104.6 million and working capital of approximately $70.3 million as of June 30, 2013.  Cash, cash equivalents, and investment securities for the second quarter of 2013 increased $18.1 million to $78.1 million compared to $60.0 million as of December 31, 2012.

Outlook

The Company expects third quarter 2013 net revenue to be in the range of approximately $93 to $96 million. Earnings per diluted share are expected to be in the range of $0.38 to $0.42 based on a 35% effective tax rate.  This compares to reported earnings per diluted share of $0.52 in the third quarter of 2012 based on a 19.7% effective tax rate. Excluding the favorable tax rate in the third quarter of 2012 and assuming a 36% effective tax rate, net income would have been $5.8 million, or $0.42 per diluted share.

For fiscal year 2013, the Company narrowed net revenue guidance to $375 to $385 million and maintained its earnings per share guidance of $1.70 to $1.80.  The Company anticipates a full year tax rate of approximately 34 to 35% in 2013.

Conference Call Information

The conference call is scheduled to begin at 4:30 p.m. ET on August 6, 2013. The call will be broadcast live over the Internet hosted at the Investor Relations section of Medifast's website at www.choosemedifast.com, and will be archived online through August 20, 2013. In addition, listeners may dial (877) 705-6003.

A telephonic playback will be available from 7:30 p.m. ET, August 6, 2013, through August 20, 2013. Participants can dial (877) 870-5176 to hear the playback and enter pass code 418058.

About Medifast

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto www.MedifastNow.com.

Forward Looking Statements

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Health Coaches and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.  

MED-F

 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS












(Unaudited)


(Audited)





June 30, 2013


December 31, 2012








ASSETS




Current assets:




Cash and cash equivalents

$              44,405,000


$             39,937,000

Accounts receivable-net of allowance for sales returns and doubtful accounts 




      of $683,000 and $542,000

1,965,000


2,148,000

Inventory

15,981,000


20,804,000

Investment securities

33,707,000


20,057,000

Income taxes, prepaid

334,000


873,000

Prepaid expenses and other current assets

2,982,000


3,296,000

Deferred tax assets

1,816,000


1,460,000

     Total current assets

101,190,000


88,575,000





Property, plant and equipment - net

40,665,000


40,109,000

Trademarks and intangibles - net

167,000


428,000

Other assets

419,000


1,139,000









     TOTAL ASSETS

$            142,441,000


$           130,251,000








LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable and accrued expenses

$              30,682,000


$             28,221,000

Current maturities of long-term debt and capital leases

247,000


528,000

     Total current liabilities

30,929,000


28,749,000








Other liabilities: 




Long-term debt, net of current portion

-


3,113,000

Capital leases, net of current portion

586,000


696,000

Deferred tax liabilities

6,378,000


6,907,000

     Total liabilities

37,893,000


39,465,000








Stockholders' Equity:




Preferred stock, $.001 par value (1,500,000 authorized, no shares issued and outstanding)

-


-

Common stock; par value $.001 per share; 20,000,000 shares authorized;




      15,542,118 and 15,525,955 issued; 13,863,043 and 13,767,380 issued and outstanding

16,000


16,000

Additional paid-in capital

41,440,000


40,191,000

Accumulated other comprehensive income 

60,000


553,000

Retained earnings 

89,540,000


76,534,000

Less: cost of 1,608,908 shares of common stock in treasury

(26,508,000)


(26,508,000)

Total stockholders' equity

104,548,000


90,786,000








TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$            142,441,000


$           130,251,000








 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)










Three Months Ended June 30,


Six Months Ended June 30,


2013


2012


2013


2012









Revenue

$        97,072,000


$        93,571,000


$      193,115,000


$      182,496,000

Cost of sales

24,142,000


23,431,000


47,776,000


45,600,000

Gross Profit

72,930,000


70,140,000


145,339,000


136,896,000









Selling, general, and administration

62,289,000


65,542,000


126,120,000


126,160,000









Income from operations

10,641,000


4,598,000


19,219,000


10,736,000









Other income








Interest and dividend income, net

98,000


90,000


150,000


162,000

Other income

139,000


814,000


219,000


938,000


237,000


904,000


369,000


1,100,000









Income before income taxes

10,878,000


5,502,000


19,588,000


11,836,000

Provision for income taxes

3,805,000


2,689,000


6,582,000


5,032,000









Net income

$          7,073,000


$          2,813,000


$        13,006,000


$          6,804,000









Basic earnings per share

$                   0.51


$                   0.20


$                   0.94


$                   0.50

Diluted earnings per share

$                   0.51


$                   0.20


$                   0.93


$                   0.49









Weighted average shares outstanding -








     Basic

13,863,043


13,747,000


13,836,087


13,711,961

     Diluted

13,963,057


13,834,264


13,995,171


13,779,595









 

The reconciliations of these non-GAAP financial measures are as follows:










Three Months Ended June 30,


Six  Months Ended June 30,


2013


2012


2013


2012









Income from operations

$     10,641,000


$       4,598,000


$     19,219,000


$          10,736,000

FTC Settlement Expense

-


3,700,000


-


3,700,000

Adjusted Income from operations 

$     10,641,000


$       8,298,000


$     19,219,000


$          14,436,000


















Three Months Ended June 30,


Six  Months Ended June 30,


2013


2012


2013


2012









Net income

$       7,073,000


$       2,813,000


$     13,006,000


$            6,804,000

FTC Settlement Expense

-


3,700,000


-


3,700,000

Adjusted Net Income

$       7,073,000


$       6,513,000


$     13,006,000


$          10,504,000









Diluted earnings per share

$                0.51


$                0.20


$                0.93


$                     0.49

Impact for adjustments

-


0.27


-


0.27

Adjusted diluted earnings per share

$                0.51


$                0.47


$                0.93


$                     0.76









The weighted-average diluted shares outstanding used in the calculation of theses non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.









Weighted average shares outstanding -








     Basic

13,863,043


13,747,000


13,836,087


13,711,961

     Diluted

13,963,057


13,834,264


13,995,171


13,779,595









 

SOURCE Medifast, Inc.

Add a Comment

News   More...

Securities related to this article
Repro-Med Systems, Inc. View repr Stock Quote
Astro-Med, Inc. View alot Stock Quote
Therma-Med, Inc. View thra Stock Quote
Quick-Med Technologies, Inc. View qmdt Stock Quote
Astro-Med, Inc. View alot Stock Quote
China Bio-Med Regeneration Technology Ltd. View 08158 Stock Quote
Med-X Systems, Inc. View mxss Stock Quote
Medifast, Inc. View med Stock Quote
Medifast, Inc. View med Stock Quote
MediClin AG View med Stock Quote
 
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - - Medifast, Inc. Announces Second Quarter 2013 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: Medifast, Inc. Announces Fourth Quarter and Fiscal Year 2013 Financial Results  |  Next: Medifast, Inc. Announces Share Repurchase